84.3% achieved at least 5% weight reduction in 60 weeks
In the long human struggle against metabolic excess, a new compound called mazdutida has emerged from a large Chinese clinical trial offering measurable hope — and measurable discomfort. Over 60 weeks, the weekly injectable reduced body weight by more than 16 percent on average, a result that dwarfs placebo and extends to patients with and without diabetes alike. Yet the body does not surrender its habits without protest, and more than half of participants experienced vomiting, reminding us that pharmaceutical progress rarely arrives without negotiation.
- Obesity affects hundreds of millions globally, yet effective medications remain scarce — mazdutida enters this gap with some of the strongest weight-loss numbers seen in a phase 3 trial.
- 461 adults across 27 Chinese hospitals lost an average of 16.65% of their body weight over 60 weeks, compared to just 1.50% in the placebo group — a gap of more than 15 percentage points.
- Over half of those taking the drug experienced vomiting, and nearly half reported nausea, raising urgent questions about whether patients outside a clinical trial will stay the course.
- The drug worked regardless of whether participants had type 2 diabetes, broadening its potential reach across a diverse population of people with moderate to severe obesity.
- Researchers and clinicians now face the central tension: weight loss this significant is rare in pharmacology, but tolerability in real-world settings remains unproven and will determine the drug's true future.
A weekly injectable drug called mazdutida has produced striking weight-loss results in a large randomized trial, offering what researchers believe could be a meaningful new option for treating moderate to severe obesity — a condition growing in prevalence worldwide while effective medications remain few.
The GLORY-2 trial, led by Dr. Leili Gao at Peking University People's Hospital, enrolled 461 Chinese adults with a BMI of 30 or higher across 27 hospitals. Participants were randomly assigned to receive either a 9-milligram weekly dose of mazdutida or a placebo, alongside dietary changes and increased physical activity, over 60 weeks. About one in six participants also had type 2 diabetes.
By the end of the trial, those on mazdutida had lost an average of 16.65 percent of their body weight, compared to just 1.50 percent in the placebo group. More than 84 percent of the treatment group achieved at least a 5 percent reduction — the threshold widely considered clinically meaningful — versus roughly a third of those on placebo. The results held whether or not participants had diabetes.
The drug's mechanism sets it apart: mazdutida activates both GLP-1 and glucagon receptor pathways, a dual action modeled on a naturally occurring mammalian hormone. But that potency comes with a cost. More than half of participants on the drug experienced vomiting, nearly half reported nausea, and about four in ten had diarrhea — rates far exceeding those in the placebo group, though most cases were mild to moderate.
Whether patients in everyday clinical settings will tolerate these side effects as readily as those in a controlled trial remains the open question. Mazdutida's ultimate place in obesity treatment will depend as much on lived tolerability as on the numbers it produces.
A new injectable medication has demonstrated the ability to help adults shed significant weight over the course of a year, offering what researchers describe as a meaningful addition to the limited pharmaceutical toolkit for treating obesity. The drug, called mazdutida, works by activating two separate receptor pathways in the body—those for glucagon and GLP-1—and is administered once weekly beneath the skin.
Obesity has become a pressing public health concern worldwide, with prevalence climbing steadily. Despite this, the arsenal of effective medications remains sparse, particularly for people dealing with moderate to severe cases. Mazdutida, a synthetic peptide modeled on a naturally occurring mammalian hormone, represents an attempt to fill that gap.
Researchers led by Dr. Leili Gao at Peking University People's Hospital conducted a large randomized trial to test whether a 9-milligram weekly dose could help Chinese adults with obesity—defined as a body mass index of 30 or higher—whether or not they also had type 2 diabetes. The GLORY-2 trial enrolled 461 participants across 27 hospitals in China between December 2023 and November 2025. Of these, 307 received mazdutida while 154 received placebo. The average participant was about 34 years old with a starting BMI of 34.3; roughly one in six had diabetes. Everyone also followed a reduced-calorie diet and increased their physical activity during the 60-week study period.
The results were substantial. Those taking mazdutida lost an average of 16.65 percent of their body weight by week 60, compared to just 1.50 percent in the placebo group—a difference of more than 15 percentage points. More strikingly, 84.3 percent of people on the medication achieved at least a 5 percent weight reduction, the threshold often considered clinically meaningful, versus only 33.1 percent of those on placebo. The effect held regardless of whether participants had diabetes.
But the medication came with a cost. More than half of those taking mazdutida—53.1 percent—experienced vomiting, compared to 1.3 percent on placebo. Nearly half reported nausea, and about four in ten had diarrhea. These gastrointestinal side effects were generally mild to moderate in severity, though their frequency raises questions about tolerability in everyday use. By contrast, the placebo group experienced these symptoms at much lower rates: 3.2 percent for nausea and 6.5 percent for diarrhea.
The trial demonstrates that mazdutida can produce clinically significant weight loss in adults with moderate to severe obesity. Whether the gastrointestinal burden will prove acceptable to patients in broader populations—beyond the controlled setting of a clinical trial—remains an open question. The medication's place in obesity treatment will likely depend on how well people tolerate these side effects over time and whether the weight loss translates into meaningful improvements in health outcomes.
Citas Notables
Mazdutida showed a clinically significant reduction of weight in adults with moderate to severe obesity compared with placebo— Study findings via Dr. Leili Gao, Peking University People's Hospital
La Conversación del Hearth Otra perspectiva de la historia
Why does this particular drug work differently from other weight-loss medications we've seen?
It activates two pathways simultaneously—glucagon and GLP-1 receptors. Most other drugs target one or the other. The dual approach seems to produce a stronger signal in the body's appetite and metabolism systems.
The side effects are pretty striking. Half the people vomited. How do you reconcile that with calling it a success?
The vomiting was mostly mild to moderate, and it happened in a controlled trial where people knew what to expect. In real life, some people might adjust or stop. But you're right—it's a real trade-off. The question is whether losing 16 percent of your body weight is worth it to you personally.
The study was all Chinese participants. Does that matter?
It matters for understanding how the drug behaves in that population specifically. But obesity is a global problem, and the underlying biology is similar across groups. Still, we'd want to see how it performs in other populations before drawing universal conclusions.
What about the people who didn't lose weight? A fifth of the drug group didn't hit 5 percent.
That's the reality of any medication—not everyone responds the same way. Some bodies are more resistant to these signals. It's why doctors will need to monitor individual responses rather than assuming it works for everyone.
Is this a cure for obesity?
No. It's a tool that helps people lose weight while they're taking it, combined with diet and exercise. The moment you stop, the weight can come back. It's management, not cure.